Intrexon Corporation (XON) has risen sharply, recording gains of 2.51% in the past 4 weeks. However, the stock has corrected -8.12% in the past 1 week, providing a good buying opportunity on dips. Intrexon Corporation (XON) : During the past 4 weeks, traders have been relatively bearish on Intrexon Corporation (XON), hence the stock is down -1.79% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -9.47% relative to the S&P 500. The stock has recorded a 20-day Moving Average of 2.33% and the 50-Day Moving Average is 7.26%.
Intrexon Corporation (NYSE:XON): The stock opened at $24.24 on Friday but the bulls could not build on the opening and the stock topped out at $24.68 for the day. The stock traded down to $24.07 during the day, due to lack of any buying support eventually closed down at $24.55 with a loss of -1.37% for the day. The stock had closed at $24.89 on the previous day. The total traded volume was 1,184,972 shares.
The company Insiders own 59.6% of Intrexon Corporation shares according to the proxy statements. Institutional Investors own 85.29% of Intrexon Corporation shares. In a related news, Kirk Randal J, CEO of Intrexon Corp, executed a transaction worth $3,714,334 on December 11, 2015. A total of 124,475 shares were purchased at an average price of $29.84. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Intrexon Corporation is engaged in the field of synthetic biology. The Company designs, builds and regulates gene programs, which are Deoxyribonucleic Acid (DNA) sequences that consist of genetic components. The Companys synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells. The Companys technologies include UltraVector, RheoSwitch Therapeutic System, Cell Systems Informatics, Protein Engineering, AttSite Recombinases, LEAP (Laser Enabled Analysis and Processing), Antibody Discovery, Neurospora & Agaricus Platforms, Endometrial Regenerative Cells, ActoBiotics, Porcine Research Models and BeyondBio. The Company serves various markets, including health, food, energy, environment and consumer. The Company has five operating divisions: Human Therapeutics, Synthetic Immunology, Animal Sciences, Agricultural Biotech, and Industrial Products.